Chatroux IC, et al. - Researchers examined the cost effectiveness of serotyping women with a history of genital herpes simplex virus (HSV) and an outbreak during the third trimester of pregnancy vs no serotyping. They used TreeAge Pro software to design a decision-analytic model to examine an approach of routine HSV serotyping in a theoretical cohort of 63,582 women (an estimate of the number of women in the United States with a history of genital HSV and an outbreak during the third trimester of pregnancy). In this theoretical cohort, 519, 8, and 15 cases of mild, moderate, and severe neonatal HSV were observed in correlation with performing HSV serology screening, whereas no serology screening resulted in 745, 65, and 85 cases, respectively. Observations suggest that outcomes may improve and costs may reduce in correlation with serology screening in pregnant women with an outbreak in the third trimester of pregnancy and a history of genital HSV.